ImmunityBio

Culver City, United States

ImmunityBio is a late-stage immunotherapy startup that is developing treatments to drive immunogenic pathways in the fight against cancer.

$80.0M raised

Jul 2025

Post-IPO Equity

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has ImmunityBio raised?

ImmunityBio has raised $80.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in July 2025.

Who are ImmunityBio's investors?

ImmunityBio's investors include Oberland Capital, Patrick Soon-Shiong, NantCapital.

Where is ImmunityBio headquartered?

ImmunityBio is headquartered in Culver City, United States.

What does ImmunityBio do?

ImmunityBio is a late-stage immunotherapy startup that is developing treatments to drive immunogenic pathways in the fight against cancer.

What stage is ImmunityBio at?

ImmunityBio is at the Post-IPO Equity stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated July 25, 2025.

MLA

"ImmunityBio — Funding & Investors." VCBacked, July 25, 2025, https://www.vcbacked.co/company/immunitybio. Accessed July 2, 2026.

APA

VCBacked. (2025). ImmunityBio — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/immunitybio

Wikipedia (cite web)

{{cite web |title=ImmunityBio — Funding & Investors |url=https://www.vcbacked.co/company/immunitybio |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated July 25, 2025.